Compare Novartis AG (NVS) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Oklo Inc — how do they compare? Novartis AG trades at $143.32 (market cap $268.57B), while Oklo Inc trades at $34.21 (market cap $6.43B). The key difference: Novartis AG is far larger — about 41.8× Oklo Inc's market cap, and Novartis AG pays a 3.31% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Oklo Inc for 31 Days on average.
| NVS | OKLO | |
|---|---|---|
Market Cap | $268.57B | $6.43B |
Volume | 1,532,573 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $168.62 | $174.14 |
52-Week Low | $121.80 | $34.57 |
Typical Hold Time | 82 Days | 31 Days |
Enterprise Value | $309.89B | $3.97B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
OKLO trades at $34.29, down 6.88% on the day, with bearish technical signals and negative earnings momentum. The company shows no revenue in 2025 and substantial losses, though it maintains strong analyst support with a $78.63 consensus price target. Recent news highlights nuclear energy sector volatility and OKLO's $1 billion stock sale activity.
OKLO represents a high-risk, high-reward opportunity in the emerging nuclear sector. While analyst consensus remains strongly bullish, the company faces significant execution risks, negative profitability, and dilution concerns from recent financing activities. The stock's potential hinges on successful project commercialization in the growing nuclear energy market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
